Overview

Efficacy Evaluation of Sabizabulin Monotherapy Versus Active Control for Treatment of ER+HER2- Metastatic Breast Cancer

Status:
Not yet recruiting

Trial end date:
2024-01-30

Target enrollment:

Participant gender:

Summary

To demonstrate the efficacy of sabizabulin in the treatment of estrogen receptor positive (ER+) metastatic breast cancer (MBC) as measured by radiographic progression free survival (rPFS).

Phase:

Phase 2

Details

Lead Sponsor:

Veru Inc.

Treatments:

Estrogen Receptor Modulators
Estrogens
Everolimus
Exemestane
Selective Estrogen Receptor Modulators